| P50 | author | Michael P. Brown | Q42068411 |
| P2093 | author name string | Amy Hsin-Chieh Hsieh | |
| | Sarah Faithfull | |
| P2860 | cites work | Characterization of a Subtype of Autoimmune Encephalitis With Anti-Contactin-Associated Protein-like 2 Antibodies in the Cerebrospinal Fluid, Prominent Limbic Symptoms, and Seizures | Q48618201 |
| | Limbic encephalitis following immunotherapy against metastatic malignant melanoma | Q48809378 |
| | Contactin-Associated Protein-like 2 Antibodies: Tackling the Issue of Syndrome Diversity. | Q51635185 |
| | Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities | Q26775383 |
| | PD-1 Blockade in Tumors with Mismatch-Repair Deficiency | Q28262647 |
| | Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer | Q29615679 |
| | Pembrolizumab versus Ipilimumab in Advanced Melanoma | Q29618134 |
| | Nivolumab in previously untreated melanoma without BRAF mutation | Q29620688 |
| | PD-1 blockade induces responses by inhibiting adaptive immune resistance | Q29620856 |
| | Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper | Q31034415 |
| | PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma | Q34667977 |
| | Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial | Q34670965 |
| | Encephalitis and antibodies to synaptic and neuronal cell surface proteins. | Q35117077 |
| | Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression. | Q37333908 |
| | A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application | Q38163290 |
| | Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice. | Q38259896 |
| | Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab | Q40393232 |
| P921 | main subject | pembrolizumab | Q13896859 |
| P577 | publication date | 2017-02-01 | |
| P1433 | published in | BMJ case reports | Q27723081 |
| P1476 | title | Risk of cumulative toxicity after complete melanoma response with pembrolizumab. | |
| P478 | volume | 2017 | |